Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Accumulated Expenses: 2016-2024

Historic Accumulated Expenses for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $15.2 million.

  • Tg Therapeutics' Accumulated Expenses rose 48.87% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 48.87%. This contributed to the annual value of $15.2 million for FY2024, which is 24.75% up from last year.
  • Per Tg Therapeutics' latest filing, its Accumulated Expenses stood at $15.2 million for FY2024, which was up 24.75% from $12.2 million recorded in FY2023.
  • Over the past 5 years, Tg Therapeutics' Accumulated Expenses peaked at $15.2 million during FY2024, and registered a low of $8.4 million during FY2022.
  • Moreover, its 3-year median value for Accumulated Expenses was $12.2 million (2023), whereas its average is $11.9 million.
  • As far as peak fluctuations go, Tg Therapeutics' Accumulated Expenses surged by 122.64% in 2020, and later fell by 17.06% in 2022.
  • Over the past 5 years, Tg Therapeutics' Accumulated Expenses (Yearly) stood at $8.5 million in 2020, then grew by 20.22% to $10.2 million in 2021, then dropped by 17.06% to $8.4 million in 2022, then spiked by 44.35% to $12.2 million in 2023, then increased by 24.75% to $15.2 million in 2024.